XSHG
688068
Market cap1.18bUSD
Oct 09, Last price
84.54CNY
1D
-1.10%
1Q
-31.99%
IPO
83.86%
Name
Beijing Hotgen Biotech Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Beijing Hotgen Biotech Co., Ltd. specializes in the complete process, from research and development to manufacturing and sales, of in-vitro diagnostic (IVD) solutions for medical and public safety purposes within the biomedical field. Their comprehensive range of products incorporates cutting-edge technologies like drug detection, CDC-compliant methods, up-conversion luminescence, colloidal gold, CLIA, sugar capture, microfluidics, and gene detection. These advanced diagnostic tools are designed to identify a broad spectrum of targets, including intestinal microorganisms, pathogens causing gastrointestinal foodborne infections, insect-borne diseases, respiratory pathogens, various infectious diseases, Ebola virus antigens, biological warfare agents, other microorganisms, and mycotoxins. The company, founded in 2005, is headquartered in Beijing, China.
Key people
Zhongchao Xie
Chief Financial Officer · since 2023
Changqing Lin
Chairman of the Board, General Manager · since 2019
Jianguo Chen
Deputy General Manager · since 2022
Xiaochi Jie
Deputy General Manager · since 2024
Yanzhao Li
Deputy General Manager · since 2025
Jia Liu
Deputy General Manager · since 2025
Haifeng Sun
Deputy General Manager · since 2018
Shaohua Yu
Deputy General Manager, Director · since 2019
Wei Min
Director of Biochemiluminescent Reagent R&D Transformation Department, Director of Reagent Quality Assurance Department · since 2019
Director · since 2025
Xiaoli Liu
Director · since 2024
Shen Qi
Director · since 2019
Yongzhan Shi
Deputy General Manager, Secretary of the Board, Director · since 2023
Lida Xu
Staff Elected Director · since 2025
Xin Zhou
Director · since 2019
Shukui Dong
Independent Director · since 2019
Independent Director · since 2019
Mengjuan Ii
Independent Director · since 2025
Xiaoge Xu
Independent Director · since 2024
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||